GLUT5 is upregulated in Philadelphia chromosome-positive ALL (Ph+ ALL), leading to imatinib resistance, thus targeting GLUT5 might be promising in Ph+ ALL patients (37, 38). The gene discussed is SLC2A5; the disease is acute lymphoblastic leukemia.